Professor of Medicine, University Tex Houston
Internal Medicine
Dr. Maureen D. Mayes, MD
|
|
Give Review
Maureen Mayes is an expert in the field of Internal Medicine. She graduated from Eastern Virginia Medical School. She received 4 awards: "America's Top Doctors", "Top Doctors:SE Texas", "Super Doctor" and "Fellow (FACR)". Maureen Mayes is also a published doctor. She has 74 publication published. The most recent publication is: The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. She accepts Medicare payments and is listed with Medicare.gov.
Publications
- The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis.
- Dissecting the Heterogeneity of Skin Gene Expression Patterns in Systemic Sclerosis.
- Reliability, validity and responsiveness to change of the Saint George's Respiratory Questionnaire in early diffuse cutaneous Systemic sclerosis.
- Identification of IL12RB1 as a Novel Systemic Sclerosis Susceptibility Locus.
- Antinuclear antibody-negative Systemic sclerosis.
- The IRF5-TNPO3 association with Systemic lupus erythematosus (SLE) has two components that other autoimmune disorders variably share.
- Identification of cadherin 11 as a mediator of dermal fibrosis and possible role in Systemic sclerosis.
- Correlates and responsiveness to change of measures of skin and musculoskeletal Disease in early diffuse systemic sclerosis.
- Multicriteria decision analysis methods with 1000Minds for developing Systemic sclerosis classification criteria.
- Development of pulmonary hypertension in a high-risk population with Systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Sclerod...
- A3.34 The global microrna profile of skin in Systemic sclerosis.
- Immunochip analysis identifies multiple susceptibility Loci for Systemic sclerosis.
- International consensus criteria for the diagnosis of Raynaud's phenomenon.
- Proteome-wide Analysis and CXCL4 as a Biomarker in Systemic Sclerosis.
- Identification of cadherin-11 as a mediator of dermal fibrosis and possible role in Systemic sclerosis.
- What does global gene expression profiling tell us about the pathogenesis of Systemic sclerosis?
- Biopsychosocial typologies of Pain in a cohort of patients with systemic sclerosis.
- Morphea in Adults and Children Cohort III: Nested Case-Control Study-The Clinical Significance of Autoantibodies in Morphea.
- Skin gene expression correlates of severity of interstitial lung Disease in systemic sclerosis.
- Implication of IL-2/IL-21 region in Systemic sclerosis genetic susceptibility.
- Measuring illness behavior in patients with Systemic sclerosis.
- Confirmation of TNIP1 but not RHOB and PSORS1C1 as Systemic sclerosis risk factors in a large independent replication study.
- Can Serum Surfactant Protein D or CC-Chemokine Ligand 18 Predict Outcome of Interstitial Lung Disease in Patients with Early Systemic Sclerosis?
- New insight on the Xq28 association with Systemic sclerosis.
- Gastric Antral Vascular Ectasia and Its Clinical Correlates in Patients with Early Diffuse Systemic Sclerosis in the SCOT Trial.
- C-reactive protein predictsthe long-term progression of interstitial lung Disease and survival in patients with early systemic sclerosis.
- Genetics of Scleroderma: implications for personalized medicine?
- The genetics of Scleroderma: looking into the postgenomic era.
- Correlation of interferon-inducible chemokine plasma levels with Disease severity in systemic sclerosis.
- Osteopontin in Systemic sclerosis and its role in dermal fibrosis.
- IRF5 polymorphism predicts prognosis in patients with Systemic sclerosis.
- New directions for patient-centred care in Scleroderma: the Scleroderma Patient-centered Intervention Network (SPIN).
- A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung Disease.
- Minimally Important Differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.
- Cigarette smoking is not a risk factor for Systemic sclerosis.
- Anti-Fibrillarin Antibody in African American Patients with Systemic Sclerosis: Immunogenetics, Clinical Features, and Survival Analysis.
- Association study of ITGAM, ITGAX, and CD58 autoimmune risk loci in Systemic sclerosis: results from 2 large European Caucasian cohorts.
- HLA-DRB1*0407 and *1304 are risk factors for Scleroderma renal crisis.
- Toll-like receptor 3 upregulation by type I interferon in healthy and Scleroderma dermal fibroblasts.
- Course of dermal ulcers and musculoskeletal involvement in systemic sclerosis patients in the Scleroderma lung study.
- Separate influences of birth order and gravidity/parity on the development of Systemic sclerosis.
- Systemic sclerosis and lupus: points in an interferon-mediated continuum.
- HLA-DPB1 and DPB2 are genetic loci for Systemic sclerosis: a genome-wide association study in Koreans with replication in North Americans.
- Polymorphisms in TBX21 and STAT4 increase the risk of Systemic sclerosis: evidence of possible gene-gene interaction and alterations in Th1/Th2 cytokines.
- Clinical and genetic factors predictive of mortality in early Systemic sclerosis.
- Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.
- Lack of evidence for bacterial infections in skin in patients with Systemic sclerosis.
- Recombinant human relaxin in the treatment of Systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial.
- MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial.
- CTGF polymorphism associated with Systemic sclerosis.
- Development of a preliminary Scleroderma gastrointestinal tract 1.0 quality of life instrument.
- High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe Systemic sclerosis: long-term follow-up of the US multicenter pilot st...
- Clinical, immunologic, and genetic features of familial Systemic sclerosis.
- Pulmonary involvement in Systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors.
- Association of the PTPN22 R620W polymorphism with anti-topoisomerase I- and anticentromere antibody-positive Systemic sclerosis.
- Macrophage migration inhibitory factor promoter polymorphisms and the clinical expression of Scleroderma.
- Gene profiling of scleroderma skin reveals robust signatures of Disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts.
- Risk of malignancy in Scleroderma: a population-based cohort study.
- Polymorphisms of endothelial nitric oxide synthase and angiotensin-converting enzyme in Systemic sclerosis.
- Classification analysis of the transcriptosome of nonlesional cultured dermal fibroblasts from systemic sclerosis patients with early Disease.
- Minocycline is not effective in Systemic sclerosis: results of an open-label multicenter trial.
- Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic ste...
- Prevalence, incidence, survival, and Disease characteristics of systemic sclerosis in a large US population.
- Scleroderma epidemiology.
- Endothelin and endothelin receptor antagonists in systemic rheumatic Disease.
- Scleroderma and solvent exposure among women.
- High-dose immunosuppressive therapy for severe Systemic sclerosis: initial outcomes.
- Partitioning of alveolar and conducting airway nitric oxide in scleroderma lung Disease.
- Right bundle branch block: a predictor of mortality in early Systemic sclerosis.
- Lack of Association of the CD247 SNP rs2056626 with Systemic Sclerosis in Han Chinese.
- Association of HLA-DPB1 with Scleroderma and Its Clinical Features in Chinese Population.
- Association of the HLA-DRB1 with Scleroderma in Chinese Population.
- Association of HLA-DQB1*0501 with Scleroderma and its clinical features in Chinese population.
Schools
Eastern Virginia Medical School Of The Medical College Of Hampton Roads
Cleveland Clinic
Procedures Preformed
- Joint Drainage
- Steroid Injection
Conditions Treated
- Adhesive Capsulitis
- Antiphospholipid Syndrome (APS)
- Arthritis
- Bursitis
- View All
Doctors Specialties
- Rheumatology
- Internal Medicine
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors:SE Texas
- Super Doctor
- Fellow (FACR)
Education
-
Cleveland Clinic Foundation -
Eastern Virginia Medical School
Drug Facts
| NPI NUMBER | 1255364238 | |
| NPPES Provider LastName | MAYES | |
| NPPES Provider FirstName | MAUREEN | |
| NPPES Provider ZIPCode | 770303000 | |
| NPPES Provider State | TX | |
| Specialty Description | Rheumatology | |
| Total Claim Count | 535.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 17.0 | |
| Percent Opioid Claims | 3.18 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1255364238 |
| Last Name Of The Provider | MAYES |
| First Name Of The Provider | MAUREEN |
| View All |
Similar Doctors
|
Dr. Tara J. Rizvi, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sachin P. Patel, MD |
|
|
Dr. Vallery M. Magee, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robby G. Wesley, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Louis Berman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David P. Huston, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Polly A. Niravath, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul G. Corn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Luz A. Dhindsa-Castanedo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Beth A. Scholz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lina M. Ching, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sarra Musa, MD
This Doctor is OpenDoctor Recommended.
|